Summit Therapeutics SMMT Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$1.08B-388% | -$221.32M+64.0% | -$614.93M-681% | -$78.78M+11.1% | ||
| $146K+64.0% | $89K-55.1% | $198K-43.3% | $349K+5.8% | ||
| $732.42M+1,337% | $50.98M+261% | $14.11M+18.1% | $11.95M-6.7% | ||
| -$322.93M-127% | -$142.11M-85.1% | -$76.76M— | —— | ||
| $657K+373% | $139K+8.6% | $128K— | —— | ||
| -$174.31M— | —— | —— | —— | ||
| $617.53M+52.5% | $404.84M+368% | $86.59M-86.0% | $620.24M+696% | ||
| —— | $33.76M+105% | -$624.82M-208% | $576.82M— | ||
| -$323.59M-127% | -$142.25M-85.0% | -$76.89M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Summit Therapeutics generate?
- Summit Therapeutics (SMMT) generated -$384.1M in operating cash flow over the trailing twelve months.
- What is Summit Therapeutics's free cash flow?
- After $480.0K of capital expenditures, Summit Therapeutics's free cash flow was -$384.5M over the trailing twelve months, down 121.4% year over year.
- Where does Summit Therapeutics's cash flow data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.